<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01192854</url>
  </required_header>
  <id_info>
    <org_study_id>XY3-III-CLV-1001A02.4</org_study_id>
    <nct_id>NCT01192854</nct_id>
  </id_info>
  <brief_title>An Study of Efficacy and Safety of Clevudine</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Positive-control, Phase III Trial of the Efficacy and Safety of Clevudine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      Randomized, double blind parallel group, positive control, multi-center trial. Patients will
      be randomized at 1:1 ratio in group A or group B
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Value of log10 hepatitis B virus (HBV) DNA decreases form baseline.</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Histological response</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of patients with hepatitis B virus (HBV) DNA below limit of detection (LOD) at week 48 with polymerase chain reaction (PCR) assay.</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients with normalization of alanine aminotransferase (ALT) at week 48</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">288</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clevudine</intervention_name>
    <description>Clevudine flexible dosages of 30 mg/day</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir</intervention_name>
    <description>Adefovir flexible dosages of 10 mg/day</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Patients are between 18 and 65, inclusive.

          2. All the male and female reproductive-aged subjects should use reliable and appropriate
             contraceptive method from the entrance of screening to at least 3 months within the
             end of study.

          3. Hepatitis B virus Early Antigen (HBeAg) positive patient with HBV DNA &gt;1 x 105
             copies/ml, HBeAg negative patient with HBV DNA &gt;1 x 104 copies/ml within 30 days of
             baseline.

          4. Absolute neutrophil count &gt; 1500 /mm3.

          5. Alpha fetoprotein within normal laboratory limit at screening.

          6. Normal electrocardiogram (ECG) or clinically non-significant changes at screening.

          7. Able to participate and willing to give written informed consent before starting
             therapy.

          8. Able and willing to comply with study assessments and restrictions.

          9. Normal renal function to take Adefovir without any dose modifications; Creatinine
             clearance must be &gt;50 ml/min (based on the Cockcroft-Gault equation.

        Exclusion criteria

          1. Subjects coinfected with human immunodeficiency virus (HIV), hepatitis A virus (HAV),
             hepatitis C virus (HCV), hepatitis D virus (HDV) or hepatitis E virus

          2. Patients previously or currently treated with approved and investigational nucleosides
             (e.g.: lamivudine, adefovir. entecavir, lobucavir, famciclovir, tenofovir,
             telbivudine) for any duration.

          3. Other chronic hepatic disease. e.g. chronic alcoholism. Wilson's disease.

          4. Poorly controlled type I or type 2 diabetes mellitus

          5. Donation or loss more than 400 ml blood within 60 days of baseline.

          6. Known serious allergies to nucleoside/nucleotide analogs.

          7. Subjects who are pregnant, nursing, or unwilling to use appropriate form of
             contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guoping Yang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xiangya Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Xiangya hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2010</study_first_submitted>
  <study_first_submitted_qc>August 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2010</study_first_posted>
  <last_update_submitted>May 13, 2013</last_update_submitted>
  <last_update_submitted_qc>May 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clevudine</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>chronic hepatitis B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
    <mesh_term>Clevudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

